Amgen in talks with FDA over Epogen, Aranesp safety labels

12/7/2007 | Reuters

California-based Amgen said it is working with the FDA to decide whether to revise warning labels on anemia drugs Aranesp and Epogen, in view of two studies that reported more deaths and incidence of tumor growth in breast and cervical cancer patients taking the drugs. The treatments already carry "black box" warnings about their link to a higher risk of death, heart attack, stroke and cancer progression.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC